Absci prices $100 million underwritten common stock offering at $7.41 per share to fund advancement of ABS-201
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $4.53M | $5.72M | $5.75M | $4.78M | $4.78M | $2.06M |
| Cost of Revenue | $62.46M | $47.57M | $58.91M | $44.59M | $11.45M | N/A |
| Gross Profit | $-57.92M | $-41.85M | $-53.16M | $-39.80M | $-6.67M | $2.06M |
| Gross Margin | -1277.57% | -731.88% | -925.02% | -832.37% | -139.50% | 100.00% |
| Operating Expenses | $50.96M | $73.67M | $53.59M | $35.43M | $6.63M | $8.32M |
| Operating Income | $-108.89M | $-115.52M | $-106.75M | $-75.24M | $-13.30M | $-6.26M |
| Operating Margin | -2401.59% | -2020.20% | -1857.49% | -1573.36% | -278.26% | -304.13% |
| Net Income | $-103.11M | $-110.57M | $-104.90M | $-100.96M | $-14.35M | $-6.58M |
| Net Margin | -2274.06% | -1933.65% | -1825.37% | -2111.25% | -300.27% | -319.61% |
| EPS (Basic) | $-0.94 | $-1.20 | $-1.15 | $-1.11 | $-0.54 | $-0.07 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |